

G: Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study. *Br J Haematol* 89:561, 1995

5. Browman GP, Bergsagel D, Sicheri D, O'Reilly S, Wilson KS, Rubin S, Belch A, Shustik C, Barr R, Walker I, James K, Zee B, Johnston D: Randomized trial of interferon maintenance in multiple

myeloma: A study of the National Cancer Institute of Canada clinical trials group. *J Clin Oncol* 13:2354, 1995

6. Ludwig H, Cohen AM, Polliak A, Huber H, Nachbaur D, Senn HJ, Morant R, Eckhardt S, Gunczler P, Seewann HL, Shuller J, Rheiner K, Cavalli F, Fritz E: Interferon alpha for induction and maintenance in multiple myeloma: Results of two multicenter randomized trials and summary of other studies. *Ann Oncol* 6:467, 1995

## Kaposi's Sarcoma-Associated Herpesvirus Is Not Detected With Immunosuppression in Multiple Myeloma

To the Editor:

Kaposi's sarcoma-associated herpesvirus (KSHV) is involved in the pathogenesis of all forms of Kaposi's sarcoma (KS).<sup>1</sup> In acquired immunodeficiency syndrome (AIDS)-associated KS, KSHV detection in peripheral blood mononuclear cells increases with immunosuppression.<sup>2</sup> Posttransplant KS are generally due to KSHV reactivation,<sup>3</sup> and complete KS remission is often achieved after reduction or cessation of immunosuppressive therapy.<sup>4</sup> Serologic studies have shown that 80% to 90% of KS patients have detectable antibodies against KSHV.<sup>5</sup> These data clearly demonstrate that KSHV is under immunological control in KS patients.

Recently, KSHV was detected in long-term cultures of bone marrow stromal cells (BMSC) with a phenotype of dendritic cells (DC)<sup>6</sup> and in bone marrow (BM) core biopsies from patients with multiple myeloma (MM).<sup>7,8</sup> The physiopathological relevance of KSHV in this interleukin-6 (IL-6)-related disease could be that it encodes for a viral IL-6 (vIL-6) able to stimulate the growth of human MM cell lines.<sup>9</sup> However, these results contradict what is known about KSHV infection and MM. Epidemiological studies show that KSHV and non-AIDS KS are found at higher incidence in Italy<sup>5</sup> and that this is clearly not the case for MM.<sup>10</sup> In addition, five groups reported a lack of antibodies against KSHV antigens in MM patients despite a normal humoral response to other herpesvirus.<sup>11-15</sup> Finally, we and others were recently unable to

found KSHV in DC samples obtained from apheresis cells of MM patients,<sup>16,17</sup> and Masood et al<sup>14</sup> failed to detect KSHV DNA in long-term BMSC cultures from MM patients. This discrepancy led us to explore the possibility that an extremely low level of KSHV infection in MM patients, leading to variable detection, may be reactivated during severe immunosuppression.

Ten patients with MM were treated with a double high-dose chemotherapy (HDC; 140 mg/m<sup>2</sup> melphalan plus 8 Gy total body irradiation) supported by autograft with purified CD34<sup>+</sup> cells (rejection of  $4.02 \pm 1.03 \times 10^6$  CD34<sup>+</sup>/kg; range, 2.88 to  $5.73 \times 10^6$ /kg). CD34<sup>+</sup> progenitors were purified by the clinical-grade method from Cellpro (Bothell, WA), leading to a 35.6-fold enrichment in hematopoietic progenitors from a mean value of  $2.4\% \pm 1.08\%$  CD34<sup>+</sup> cells (range, 0.99% to 3.47%) before purification to  $85.4\% \pm 7.1\%$  CD34<sup>+</sup> cells (range, 72.4% to 92.8%) after purification. The resulting graft was 1,407-fold depleted of T cells (rejection of  $0.11 \pm 0.08 \times 10^6$  CD3<sup>+</sup> cells/kg; range, 0.05 to  $0.25 \times 10^6$ /kg). Four of 10 patients relapsed within 1 year. The peripheral blood CD4<sup>+</sup> T-cell count was monitored at 3, 6, and 12 months after the second purified autograft. Eight of 10 patients had less than 200 CD4<sup>+</sup> cells/ $\mu$ L for at least 3 months, with a mean duration of 7 months for the 6 evaluable over 1 year (Table 1). Many infectious events arose during this first year after second HDC (median of 3 episodes per patient). In particular, 7 of 10 patients suffered from herpesvirus reactivation (Table 1). Because KS has rarely

Table 1. CD4<sup>+</sup> T-Cell Counts and Infectious Events in Autografted MM Patients

Patient No.	No. of CD4 <sup>+</sup> T Cells/ $\mu$ L				Cumulative No. of Months With CD4 <sup>+</sup> T Cells <200/ $\mu$ L	Infectious Events After Second HDC*
	Before First HDC	Day 90 After Second HDC	Day 180 After Second HDC	Day 360 After Second HDC		
1	892	170	291	266	4	VZV, CMV
2	361	91	11	351	6	VZV, CMV
3	350	95	150	146	8	HZV, CMV
4	315	327	307	234	0	HSV
5	259	77	75	88	12	Other
6	369	168	148	160	12	CMV, Other
7	430	140	149	†	11/11‡	Other
8	593	310	ND	†	0	CMV
9	124	64	199	§	6/6‡	
10	412	128	†	†	4/4‡	CMV
Mean $\pm$ SD	410.5 $\pm$ 207.5	157 $\pm$ 92.5	166.2 $\pm$ 99.8	207.5 $\pm$ 94.9		

CD4<sup>+</sup> T-cell count was monitored by flow cytometry.


Abbreviation: ND, not done.

\*Viral manifestation of varicella (VZV), zoster (HZV), herpes (HSV), other virus (Other), or cytomegalovirus antigen detection (CMV).

†Patient died before evaluation.

‡CD4 count could be evaluated only during the indicated time.

§Patient has not reached day 360 after HDC.



**Fig 1.** Lack of KSHV reactivation during treatment-induced immunosuppression in MM patients. (A) DNA samples extracted from BM before and 90, 180, and 360 days after second HDC were amplified by PCR using the KSHV 330<sub>233</sub> primers. Each PCR was performed on 1 µg of genomic DNA and the amplification products were transferred to a nylon membrane and hybridized with a <sup>32</sup>P end-labeled internal probe. The positive control (lane C) was the PCR product from the KSHV-infected BCBL-1 cell line. (B) Lanes 1 through 5 contain 10-fold dilutions of BCBL-1 DNA from 1 ng (lane 1) to 0.1 pg (lane 5). BCBL-1 DNA was diluted in the DNA extracted from heparinized BM mononuclear cells from patient no. 1 90 days after the second HDC, so that all PCR were run on 1 µg of total DNA. These data are representative of 10 experiments performed with the heparinized DNA samples extracted from the 10 patients 90 days after second HDC.

been associated with hematopoietic stem cell transplantation, no kinetic study was available; thus, repeated polymerase chain reaction (PCR) amplification was performed to detect KSHV in BM samples harvested before and 90, 180, and 360 days after the second HDC. KSHV DNA was monitored in 1 µg of genomic DNA (ie, 150,000 cells), in a blinded fashion and in two different laboratories, using a PCR assay against the KS330<sub>233</sub> KSHV sequence.<sup>1</sup> This sensitive method allowed the detection of KSHV DNA in less than 1 pg of genomic DNA from the KSHV-infected BCBL-1 cell line that corresponds to approximately 5 KSHV genome copies.<sup>16,18</sup> KSHV DNA was not detected in any of the 35 BM samples tested (Fig 1). The lack of KSHV detection was not due to the presence of Taq polymerase inhibitors, in particular heparin, because the sensitivity of KSHV PCR was the same when assayed with either DNA harvested from heparinized BM mononuclear cells or DNA from cells collected without heparin (Fig 1).

Three explanations may account for the discrepancy between the negative PCR with BM aspirates, the negative serological results, the lack of KSHV reactivation in immunosuppressed MM patients, and the positive PCR with stromal cultures and BM biopsies. (1) MM patients could be infected with a variant of KSHV that can escape the immune system or that encodes for antigens not recognized by the available immunological assays. This could explain the failure to detect anti-KSHV antibodies. (2) KSHV could be under a strict T-cell-mediated immune control in MM patients, leading to a very difficult detection by sensitive PCR. In this case, because infected cells remain undetectable in whole BM samples after double HDC and graft of purified CD34<sup>+</sup> cells, one could hypothesize that this treatment has not destroyed anti-KSHV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, contrary to other anti-herpesvirus T cells. (3) KSHV could be not involved in MM patients, and its detection could be linked to false-positive PCR, as pointed out recently by Moore.<sup>19</sup>

These contradictions need to be elucidated, but our present results emphasize that, if KSHV or a variant of KSHV is really involved in MM, it is not a major factor in relapse occurring in immunosuppressed patients after autologous graft and raises the question of its causal role in MM.

Karin Tarte  
 IGMM  
 CNRS  
 Montpellier, France  
 Sonja J. Olsen  
 Division of Epidemiology  
 Columbia University  
 New York, NY  
 Jean-François Rossi  
 Eric Legouffe  
 Service d'Hématologie et d'Oncologie Médicale  
 CHU Lapeyronie  
 Montpellier, France  
 Zhao-Yang Lu  
 Michel Jourdan  
 U475, INSERM  
 Montpellier, France  
 Yuan Chang  
 Department of Pathology  
 Columbia University  
 New York, NY  
 Bernard Klein  
 Unité de Thérapie Cellulaire  
 CHU Saint Eloi  
 Montpellier, France

## REFERENCES

1. Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. *Science* 266:1865, 1994
2. Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FE, Aldam DM, Denton AS: Detection of Kaposi sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. *Lancet* 346:799, 1995
3. Parravicini C, Olsen SJ, Capra M, Poli F, Sirchia G, Gao SJ, Berti E, Nocera A, Rossi E, Bestetti G, Pizzuto M, Galli M, Moroni M, Moore PS, Corbellino M: Risk of Kaposi's sarcoma-associated herpes virus transmission from donor allografts among Italian posttransplant Kaposi's sarcoma patients. *Blood* 90:2826, 1997
4. Penn I: Sarcomas in organ allograft recipients. *Transplantation* 60:1485, 1995
5. Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS: KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. *Nat Med* 2:925, 1996
6. Rettig MB, Ma HJ, Vescio RA, Pold M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR: Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients. *Science* 276:1851, 1997
7. Said JW, Rettig MR, Heppner K, Vescio RA, Schiller G, Ma HJ, Belson D, Savage A, Shintaku IP, Koeffler HP, Asou H, Pinkus G, Pinkus J, Schrage M, Green E, Berenson JR: Localization of Kaposi's sarcoma-associated herpesvirus in bone marrow biopsy samples from patients with multiple myeloma. *Blood* 90:4278, 1997
8. Brousset P, Meggetto F, Attal M, Delsol G: Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma [letter]. *Science* 278:1972, 1997
9. Burger R, Neipel F, Fleckenstein B, Savino R, Ciliberto G, Kalden JR, Gramatzki M: Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. *Blood* 91:1858, 1998
10. Masala G, Di Lollo S, Picoco C, Crosignani P, Demicheli V, Fontana A, Funto I, Miligi L, Nanni O, Papucci A, Ramazzotti V, Rodella S, Stagnaro E, Tumino R, Vigano C, Vindigni C, Seniori Costantini A, Vineis P: Incidence rates of leukemias, lymphomas and myelomas in Italy: Geographic distribution and NHL histotypes. *Int J Cancer* 68:156, 1996
11. Marcelin AG, Dupin N, Bouscary D, Bossi P, Cacoub P, Ravaud P, Calvez V: HHV-8 and multiple myeloma in France [letter]. *Lancet* 350:1144, 1997
12. MacKenzie J, Sheldon J, Morgan G, Cook G, Schulz TF, Jarrett RF: HHV-8 and multiple myeloma in the UK [letter]. *Lancet* 350:1144, 1997
13. Parravicini C, Lauri E, Baldini L, Neri A, Poli F, Sirchia G, Moroni M, Galli M, Corbellino M: Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma [letter]. *Science* 278:1969, 1997
14. Masood R, Zheng T, Tupule A, Arora N, Chatlynne L, Handy M, Whitman J Jr.: Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma [letter]. *Science* 278:1970, 1997
15. Whitby D, Boshoff C, Luppi M, Torelli G: Kaposi's sarcoma-associated herpesvirus infection and multiple myeloma [letter]. *Science* 278:1971, 1997
16. Tarte K, Olsen SJ, Lu ZY, Legouffe E, Rossi JF, Chang Y, Klein B: Clinical grade functional dendritic cells from patients with multiple myeloma are not infected with Kaposi's sarcoma-associated herpesvirus. *Blood* 91:1852, 1998
17. Cull GM, Timms JM, Haynes AP, Russell NH, Irving WL, Ball JK, Thomson BJ: Dendritic cells cultured from mononuclear cells and CD34 cells in myeloma do not harbour human herpesvirus 8. *Br J Haematol* 100:793, 1998
18. Parry JP, Moore PS: Corrected prevalence of Kaposi's sarcoma (KS)-associated herpesvirus infection prior to onset of KS [letter]. *AIDS* 11:127, 1997
19. Moore PS: Human herpesvirus 8 variants [letter]. *Lancet* 351:679, 1998

## Cytoplasmic Interleukin-4 (IL-4) and Surface IL-4 Receptor Expression in Patients With B-Cell Lymphocytic Leukemia

To the Editor:

B-cell chronic lymphocytic leukemia (B-CLL) is a malignancy characterized by the accumulation of long-lived CD5<sup>+</sup> cells<sup>1</sup> in which cytokines might be involved in the proliferation and survival of malignant B cells.<sup>2-6</sup>

In particular, interleukin-4 (IL-4) prevents B-CLL cell clones from entering spontaneous apoptosis by increasing the expression of bcl-2<sup>5</sup> and protects B-CLL cells against anti-APO1-induced apoptosis.<sup>6</sup> Only one report has analyzed the intracellular expression of IL-4 in T cells of patients with B-CLL.<sup>7</sup> We examined the expression of IL-4 and IL-4 receptor (IL-4R) in unstimulated leukemic B cells and T cells from 10 patients with untreated stage A B-CLL and compared them with 10 normal controls using flow cytometric analyses.

We found that the proportion of CD19<sup>+</sup> cells expressing cytoplasmic IL-4 was significantly higher in B-CLL patients than in controls ( $P < .002$ ; Table 1). The proportion of CD3<sup>+</sup> cells expressing cytoplasmic IL-4 was significantly higher in B-CLL patients than in controls ( $P < .02$ ). Although the proportion of CD19<sup>+</sup> cells expressing IL-4R

was similar, the proportion of CD3<sup>+</sup> cells expressing the IL-4R in B-CLL patients was significantly higher than in normal controls ( $P < .02$ ). IL-4 could not be detected in the supernatant after the in vitro culture of the cells from both patients and controls. After stimulation with the mitogen PWM, six of the seven control samples and none of the patient cells had detectable supernatant IL-4 ( $P < .03$ ; Table 2).

The demonstration that T cells from B-CLL patients display a greater percentage of IL-4R expression from normal individuals is novel. It is unclear whether the T cells from B-CLL patients express both the IL-4R together with IL-4 or this aberrant expression occurs on different T-cell populations in these patients. It is intriguing that no increase in IL-4R expression could be found on malignant B-CLL cells despite the expression of cytoplasmic IL-4. It is possible that the IL-4 from the B-CLL B cells is released and taken up rapidly by the T cells, and this leads to the aberrant expression of the IL-4R. Alternatively, the interaction between the malignant B cells and T cells may occur in a microenvironment in which local concentrations of IL-4 may be high, but these are not reflected in the blood. The disproportionate relationship between IL-4 and its receptor in the normal T-cell compartment compared with the malignant B-cell compartment in B-CLL is presum-